Bullet points25 Jan 2023 13:13
1 estimated revenue in 2022 of GBP50.6 million, surging 30% from GBP39 million in 2021.
2 validation of the long-term sustainable growth in the human challenge trial market,"
3 expects to report earnings before interest, tax, depreciation and amortisation margins of at least 17% (not clear precisely what this means. 17% of what? Can anyone elucidate?)
4 margin improvement was a result of strong trading in the second half of the year. But £1m due to one-off cancellation fees
5 cash position at December 31 was GBP28.4 million, up from GBP15.7 million a year ago, due to advanced fees
6 orderbook was GBP76 million at year-end, up 65% from GBP46 million a year before, due to a number of large contracts with biopharma clients.
7 There has been an increase in the average value of each challenge trial contract
Update harps heavily on successes in revenue, but seems reluctant to discuss profitability?